Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV

HIV / AIDS

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

HIV Med.

Ryom L, Cotter A, De Miguel R, Béguelin C, Podlekareva D, Arribas JR, Marzolini C, Mallon P, Rauch A, Kirk O, Molina JM, Guaraldi G, Winston A, Bhagani S, Cinque P, Kowalska JD, Collins S, Battegay M, EACS Governing Board.

doi: 10.1111/hiv.12878.

HIV / AIDS

Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence

HIV Med

Punekar YS, Parks D, Joshi M, Kaur S, Evitt L, Chounta V, Radford M, Jha D, Ferrante S, Sharma S, Van Wyk J, de Ruiter A

doi: 10.1111/hiv.13050

HIV / AIDS

Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort

HIV Med

Fabbiani M, Rossetti B, Ciccullo A, Oreni L, Lagi F, Celani L, Colafigli M, De Vito A, Mazzitelli M, Dusina A, Durante M, Montagnani F, Rusconi S, Capetti A, Sterrantino G, D'Ettorre G, Di Giambenedetto S, ODOACRE Study Group.

doi: 10.1111/hiv.13146

Further Publications AnesthesiologyFurther Publications PainFurther Publications Infectiology

Uptake and effectiveness of two-drug compared to three-drug antiretroviral Regimens among HIV-positive Individuals in Europe

AIDS.

Neesgaard B, Pelchen-Matthews A, Ryom L, Florence E, Peters L, Roen A, Svedhem V, Clarke A, Benfield T, Mitsura V, Moreno S, Beniowski M, Begovac J, Matulionyte R, Trofimova T, Elbirt D, Kundro M, Vullo V, Behrens G, Staub T, Ragone L, Vannappagari V, Lundgren J, Mocroft A, EuroSIDA study.

doi: 10.1097/QAD.

HIV / AIDS

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

Lancet HIV.

Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H, GS-US-380-1489., GS-US-380-1490 study investigators.

doi: 10.1016/S2352-3018(20)30099-0.

SPECIAL REPORT

HIV / AIDS

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

HIV / AIDS

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study

Clin Infect Dis.

van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla J, Routy JP, Wyen C, Ait-Khaled M, Nascimento MC, Pappa KA, Wang R, Wright J, Tenorio AR, Wynne B, Aboud M, Gartland MJ, Smith KY

doi: 10.1093/cid/ciz1243.

HIV / AIDS

Escitalopram population pharmacokinetics in people living with HIV and in the psychiatric population: drug-drug interactions and probability of target attainment

Br J Clin Pharmacol.

Courlet P, Guidi M, Glatard A, Alves Saldanha S, Cavassini M, Buclin T, Marzolini C, Eap CB, Decosterd LA, Csajka C, Swiss HIV Cohort Study.

doi: 10.1111/bcp.13994.

HIV / AIDS

HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial

Lancet HIV

Korthuis PT, King C, Cook RR, Khuyen TT, Kunkel LE, Bart G, Nguyen T, Thuy DT, Bielavitz S, Nguyen DB, Tam NTM, Giang LM

doi: 10.1016/S2352-3018(20)30302-7

Related content

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence

Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort

Uptake and effectiveness of two-drug compared to three-drug antiretroviral Regimens among HIV-positive Individuals in Europe

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study

Escitalopram population pharmacokinetics in people living with HIV and in the psychiatric population: drug-drug interactions and probability of target attainment

HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial